Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017
Montag, 30.10.2017 13:35 von PR Newswire
PR Newswire
BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2017
Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com
BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2017 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will be presenting live at VirtualInvestorConferences.com on November 2, 2017.
View investor presentations 24/7 at www.virtualinvestorconferences.com . (PRNewsFoto/OTC Markets Group Inc.)
Achieve will be providing a brief history of the company, an update on cytisine and its clinical development program, including current phase 1 studies and near-term Phase 3 plans. Investors will have the opportunity to ask questions in real-time, as this is a live, interactive online event. Questions may be asked both in the presentation hall and in the association's "virtual trade booth." Should attendees not be able to join on the day, an on-demand archive will be made available for 90 days after the webcast.
"We are extremely pleased to have been invited to present at this live, interactive event. It is an excellent opportunity for us to provide an update on our company and clinical development plans for cytisine," said Rick Stewart.
Achieve will present on Thursday, November 2, 2017 at 1:00 PM at https://tinyurl.com/112prepr. It is recommended that attendees pre-register to receive event updates in advance: www.VirtualInvestorConferences.com.
About Achieve and Cytisine
Achieve is developing cytisine as a smoking cessation aid. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including approximately 2,000 patients in Phase 3 clinical trials conducted in Europe and New Zealand. Achieve's focus is to address the global smoking health epidemic, which is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide. Discussions have been held with the FDA and European regulatory agencies to determine the clinical and regulatory pathway towards making cytisine widely available.
About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of and plans for clinical development of cytisine, the market size for cytisine and the potential benefits of cytisine. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisine may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisine; the risk that cytisine will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including the final Proxy Statement/Prospectus/Information Statement filed pursuant to Rule 424(b)(3) in connection with Achieve's recent merger, and Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
View original content with multimedia:http://www.prnewswire.com/news-releases/...mber-2-2017-300545322.html
SOURCE Achieve Life Sciences, Inc.
|
Thread abonnieren
